The forecast for antibacterial medicine sales in Canada from 2024 to 2028 shows a steady decline. Actual data from 2023 indicated sales at 378.5 million USD PPP. Year-on-year variations highlight a decreasing trend: a drop from 2024 to 2025 by approximately 4.3%, from 2025 to 2026 by about 4.4%, from 2026 to 2027 by roughly 4.7%, and from 2027 to 2028 by nearly 4.8%. The Compound Annual Growth Rate (CAGR) over the five-year period indicates an average annual decline of around 4.8%.
Future trends to watch for include the development of antibiotic resistance, shifts towards more personalized and advanced treatment options, and the potential for stricter regulations and policies impacting the antibacterial medicine market. These factors could either exacerbate the decline or stabilize the trend depending on market adaptations and innovations.
